var data={"title":"Paricalcitol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Paricalcitol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6725?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=paricalcitol-drug-information\" class=\"drug drug_general\">see &quot;Paricalcitol: Drug information&quot;</a> and <a href=\"topic.htm?path=paricalcitol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Paricalcitol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206463\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zemplar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206464\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zemplar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029635\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vitamin D Analog</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Fat Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029664\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=paricalcitol-drug-information\" class=\"drug drug_general\">see &quot;Paricalcitol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary</b>\n      <b> hyperparathyroidism associated with stage 5 chronic renal failure (CKD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> Calculate based on intact parathyroid hormone (iPTH) serum levels using the following equation. Round the calculated dose <b>down</b> to the nearest whole number and administer calculated dose 3 times/week and no more frequently than every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial dose (mcg) = baseline iPTH (pg/ml) divided by 120</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Titration:</i> Every 4 weeks, may increase dose by 1 mcg/dose (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. Based on response and clinical markers (iPTH, serum Ca, and P), each administered dose may be decreased 2 mcg/dose at any time. If dosage reduction is required while receiving 1 or 2 mcg 3 times/week, discontinue therapy and resume when appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: <b>Note: </b>To reduce the risk of hypercalcemia, initiate only after baseline serum calcium has been adjusted to &le;9.5 mg/dL. In patients where laboratory markers are monitored less frequently than once weekly, more modest dosing should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose:</i> Calculate based on iPTH serum levels using the following equation and administer calculated dose 3 times/week and no more frequently than every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial dose (mcg) = baseline iPTH (pg/mL) divided by 80</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Titration</i>\n      <i>: </i>Adjust mcg dose based on at least weekly labs (iPTH, Ca, and P); administer calculated dose 3 times/week and not more often than every other day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">iPTH level (pg/mL) based: Dose (mcg) = Most recent iPTH level (pg/mL) divided by 80</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Elevated serum calcium: Decrease dose by 2 to 4 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>For modest dosing adjustments: </i>In situations where monitoring of iPTH, calcium, and phosphorus occurs less frequently than once per week, a more modest initial and dose titration rate may be warranted. Calculate based on iPTH serum levels using the following equation and administer calculated dose 3 times/week and no more frequently than every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Modest dose (mcg) = Most recent iPTH level (pg/mL) divided by 100</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Parenteral: Children &ge;5 years and Adolescents: IV through HD access (not directly into vein):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial and Titration:</i> 0.04 to 0.1 mcg/kg/dose; administer anytime during dialysis sessions but no more frequently than every other day; titrate by 0.04 to 0.1 mcg/kg/dose every 2 to 4 weeks (in adults, usual increment is 2 to 4 mcg/dose). In one pediatric trial, mean dose requirement was 0.2 &plusmn; 0.7 mcg/kg/dose (range: 0.1 to 0.9 mcg/kg/dose) (Seeherunvong 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosing adjustment:</i> The dose of paricalcitol should be adjusted based on iPTH levels relative to baseline and targets as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Above target and increasing iPTH level: Increase paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Above target and iPTH level decreased by &lt;30%: Increase paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Above target and iPTH level decreased by &ge;30% and &le;60%: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Above target and iPTH level decrease by &gt;60%: Decrease paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">At target and iPTH stable: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with stage 3 and 4 chronic renal failure (CKD<b>)</b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;10 years and Adolescents &le;16 years: Oral: Initial: 1 mcg 3 times/week no more frequently than every other day; may titrate every 4 weeks; increase dose by 1 mcg (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. Based on response and clinical markers (iPTH, serum Ca, and P), each administered dose may be decreased by 1 mcg at any time. If dosage reduction is required while receiving 1 mcg 3 times/week, discontinue therapy, resuming when appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;17 years: <b>Note:</b> If using 3 times/week dosing, doses should not be administered more frequently than every other day: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial: </i>Dose based on baseline serum iPTH:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH &le;500 pg/mL: 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH &gt;500 pg/mL: 2 mcg once daily or 4 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Titration</i>\n      <i> and dosage adjustment: </i>May adjust at 2 to 4 week intervals based on iPTH level relative to baseline; if using 3 times/week dosing, doses should not be administered more frequently than every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH same or increased: Increase paricalcitol dose <b>by</b> 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH decreased by &lt;30%: Increase paricalcitol dose <b>by</b> 1 mcg once daily or 2 mcg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH decreased by &ge;30% and &le;60%: Maintain paricalcitol dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH decreased by &gt;60%: Decrease paricalcitol dose <b>by </b>1 mcg/day or 2 mcg 3 times/week (see <b>Note</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">iPTH &lt;60 pg/mL: Decrease paricalcitol dose <b>by</b> 1 mcg/day or 2 mcg 3 times/week (see <b>Note</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b> Note:</b> If patient is taking the lowest dose (1 mcg) on the daily regimen and an additional dose reduction is necessary, then regimen should be changed to 1 mcg 3 times weekly. If further reduction is required, withhold drug as needed and restart at a lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> Adjustment not needed for mild-to-moderate impairment. Paricalcitol has not been evaluated in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206452\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar: 1 mcg, 2 mcg, 4 mcg [DSC] [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg, 2 mcg, 4 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206438\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029671\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered with or without food. With the 3 times/week dosing schedule, doses should not be given more frequently than every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer undiluted as an IV bolus through hemodialysis port at any time during dialysis. Doses should not be administered more often than every other day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10493725\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029636\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prevention and treatment of secondary hyperparathyroidism associated with stage 5 chronic kidney disease (CKD) (FDA approved in ages &ge;5 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Prevention and treatment of secondary hyperparathyroidism associated with stages 3 and 4 CKD and stage 5 CKD patients on hemodialysis or peritoneal dialysis (FDA approved in ages &ge;10 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7297725\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound alike/look alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Paricalcitol may be confused with calcifediol, calcitriol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zemplar may be confused with zaleplon, Zelapar, zolpidem, ZyPREXA Zydis</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206487\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial flutter, cardiac arrhythmia, cerebrovascular accident, chest discomfort, chest pain, edema, hypertension, hypotension, ischemic bowel disease, palpitations, peripheral edema, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, agitation, anxiety, chills, confusion, delirium, depression, dizziness, fatigue, headache, hypoesthesia, insomnia, malaise, myoclonus, nervousness, paresthesia, restlessness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, burning sensation of skin, dermal ulcer, ecchymoses, extravasation reactions, night sweats, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, hirsutism, hypercalcemia, hyperkalemia, hyperparathyroidism, hyperphosphatemia, hypervolemia, hypocalcemia, hypoglycemia, hypoparathyroidism, increased thirst, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dysgeusia, dyspepsia, dysphagia, gastritis, gastroesophageal reflux disease, gastrointestinal hemorrhage, nausea (children, adolescents, and adults), peritonitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Chronic renal failure, erectile dysfunction, mastalgia, uremia, urinary tract infection, urinary urgency (children and adolescents), vaginal infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, lymphadenopathy, malignant neoplasm of breast, prolonged bleeding time, rectal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection (bacterial, fungal, viral), influenza, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, joint stiffness, leg cramps, muscle spasm, muscle twitching, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis (more common in children and adolescents), glaucoma, ocular hyperemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma (children and adolescents), bronchitis, cough, dyspnea, nasopharyngitis, oropharyngeal pain, orthopnea, pneumonia, pulmonary edema, rhinitis (children and adolescents), sinusitis, upper respiratory tract infection, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, laboratory test abnormality, swelling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema (including laryngeal edema), increased serum creatinine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206457\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to paricalcitol or any component of the formulation; vitamin D toxicity; hypercalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for vitamin D analogues is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206442\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia. Risk of hypercalcemia may be increased by concomitant use of calcium-containing supplements and/or medications that increase serum calcium (eg, thiazide diuretics).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535370\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730134\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206447\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13032&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Paricalcitol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Paricalcitol may enhance the adverse/toxic effect of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with orlistat. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of orlistat<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206448\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F730133\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029674\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of vitamin D intoxication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium and phosphorus (closely monitor levels during dosage titration and after initiation of a strong CYP3A4 inhibitor):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Twice weekly during initial phase, then at least monthly once dose established</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">KDIGO 2017 guidelines: <b>Note:</b> Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CKD</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Phosphorous</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Alkaline Phosphatase</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">PTH</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G2 to G3b</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Based on clinical condition</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Based on baseline and progression of disease</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 12 months (more often in presence of elevated PTH)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G5 and G5d</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 1 to 3 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 1 to 3 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 12 months (more often in presence of elevated PTH)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029656\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Target range for iPTH:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 2 CKD: Children: 35 to 70 pg/mL (3.85 to 7.7 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stage 3 CKD: Children and Adults: 35 to 70 pg/mL (3.85 to 7.7 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stage 4 CKD: Children and Adults: 70 to 110 pg/mL (7.7 to 12.1 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Stage 5 CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 200 to 300 pg/mL (22 to 33 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: 150 to 300 pg/mL (16.5 to 33 pmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum phosphorous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stages 1 to 4 CKD: Children: At or above the age-appropriate lower limits and no higher than age-appropriate upper limits</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 3 and 4 CKD: Adults: &ge;2.7 to &lt;4.6 mg/dL (&ge;0.87 to &lt;1.49 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 5 CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 12 years: 4 to 6 mg/dL (1.29 to 1.94 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;12 years and Adults: 3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206441\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreased renal conversion of vitamin D to its primary active metabolite (1,25-hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor (VDR), which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption. Paricalcitol is a synthetic vitamin D analog which binds to and activates the VDR in kidney, parathyroid gland, intestine and bone, thus reducing PTH levels and improving calcium and phosphate homeostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206456\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Healthy subjects: Oral: 34 L; IV: 24 L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stage 3 and 4 CKD: Oral: 44 to 46 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stage 5 CKD: Oral: 38 to 49 L; IV: 31 to 35 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hydroxylation and glucuronidation via hepatic and nonhepatic enzymes, including CYP24, CYP3A4, UGT1A4; forms metabolites (at least one active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 72% to 86% in healthy subjects</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Healthy subjects: Oral: 4 to 6 hours; IV: 5 to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Stage 3 and 4 CKD: Oral: 17 to 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Stage 5 CKD (on HD or PD): Oral: 14 to 18 hours; IV: 14 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 3 hours: Delayed by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Healthy subjects: Feces (oral: 70%; IV: 63%); urine (oral: 18%, IV: 19%); 51% to 59% as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51157229\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic kidney disease (CKD):</b> Children &ge;2 years, Adolescents, and Adults: CKD is defined as GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &gt;3 months; GFR category, albuminuria category, and cause of kidney damage are used in conjunction to assign a stage (KDIGO 2012; KDIGO 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR categories:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G1: Normal or increased GFR; GFR &ge;90 mL/minute/1.73 m<sup>2 </sup>WITH kidney damage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G2: Mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup> WITH kidney damage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G3a: Mild to moderate decrease in GFR; GFR 45 to 59 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G3b: Moderate to severe decrease in GFR; GFR 30 to 44 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD G4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD G5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Albuminuria categories:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A1: Normal or mildly increased</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A2: Moderately increased</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A3: Severely increased</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422271\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Paricalcitol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg (30): $332.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg (30): $665.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg (30): $1,330.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zemplar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg (30): $468.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg (30): $936.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Paricalcitol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg/mL (1 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/mL (1 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zemplar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg/mL (1 mL): $7.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mcg/mL (1 mL): $18.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206458\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Paricon (BD);</li>\n      <li>Paritol (BD);</li>\n      <li>Zemplar (AE, AR, AT, BB, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, FI, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IT, JO, KR, KW, LT, LV, MT, MX, MY, NI, NL, NO, PA, PE, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TR, TW, UA, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenbaum LA, Benador N, Goldstein SL, et al, &quot;Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis,&quot; <i>Am J Kidney Dis</i>, 2007, 49(6):814-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/17533024/pubmed\" target=\"_blank\" id=\"17533024\">17533024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46(4 Suppl 1):S1-121.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 1. Evaluation of calcium and phosphorus metabolism. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):52-57.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 3. Evaluation of serum phosphorus levels. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):62-63.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease,&quot; <i>Am J Kidney Dis</i>, 2002, 39(2 Suppl 1):46-75.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2009;(113):S1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2017;7:1-59.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl</i>. 2013;(3):1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez CP, &ldquo;Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(11): 763-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/14580225/pubmed\" target=\"_blank\" id=\"14580225\">14580225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seeherunvong W, Nwobi, O, Abitbol CL, et al, &ldquo;Paricalcitol Versus Calcitriol Treatment for Hyperparathyroidism in Pediatric Hemodialysis Patients,&rdquo; <i>Pediatr Nephrol</i>, 2006, 21(10):1434-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/16900383/pubmed\" target=\"_blank\" id=\"16900383\">16900383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemplar (paricalcitol capsules) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zemplar (paricalcitol injection) [prescribing information]. Lake Forest, IL; Hospira Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ziolkowska H, &ldquo;Minimizing Bone Abnormalities in Children With Renal Failure,&rdquo; <i>Paediatr Drugs</i>, 2006, 8(4):205-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/16898852/pubmed\" target=\"_blank\" id=\"16898852\">16898852</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13032 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206463\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206464\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1029635\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1029664\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206452\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206438\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1029671\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10493725\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1029636\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7297725\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206487\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206457\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206442\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535370\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F730134\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206447\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206448\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F730133\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1029674\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1029656\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206441\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206456\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F51157229\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422271\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206458\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13032|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=paricalcitol-drug-information\" class=\"drug drug_general\">Paricalcitol: Drug information</a></li><li><a href=\"topic.htm?path=paricalcitol-patient-drug-information\" class=\"drug drug_patient\">Paricalcitol: Patient drug information</a></li></ul></div></div>","javascript":null}